The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS)

The work of two years of the Task Force in charge of the new European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension has finally come to an end. The new guidelines were officially presented yesterday at the ESC Annual Congress in Barcelona […]

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Read Post »

“Prevalence of mental disorders and impact on quality of life in patients with pulmonary arteriaI hypertension”, Frontiers in Psychiatry

Three patient representatives (Ralf Schmiedel, Pisana Ferrari, Hans-Dieter Kulla) contributed to the study and article. The first two are patients having undergone lung transplant, Mr Kulla is the President of ph e.v., German PH association. The other authors are Karen M. Olsson, Tanja Meltendorf, Manuel J Richter, Jan Fuge, Jan Christopher Kamp, Da-Hee Park, Henning

“Prevalence of mental disorders and impact on quality of life in patients with pulmonary arteriaI hypertension”, Frontiers in Psychiatry Read Post »

“Sotatercept for the Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine

Marc Humbert, M.D., Ph.D.,  Vallerie McLaughlin, M.D.,  J. Simon R. Gibbs, M.D.,  Mardi Gomberg-Maitland, M.D.,  Marius M. Hoeper, M.D.,  Ioana R. Preston, M.D.,  Rogerio Souza, M.D., Ph.D.,  Aaron Waxman, M.D., Ph.D.,  Pilar Escribano Subias, M.D., Ph.D.,  Jeremy Feldman, M.D.,  Gisela Meyer, M.D.,  David Montani, M.D., Ph.D.,  et al.,  “Sotatercept for the Treatment of Pulmonary Arterial

“Sotatercept for the Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine Read Post »

“Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience”, European Respiratory Review

A very interesting article about epoprostenol, the first ever therapy to be approved for the treatment of pulmonary arterial hypertension. The development of epoprostenol followed on from the discovery of endogenous prostacyclins in the vasculature by Sir Salvator Moncada et al. in the 1970s. Shortly after this, epoprostenol was synthesised and shown to have anti-platelet activity

“Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience”, European Respiratory Review Read Post »

“Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?”, European Respiratory Review, December 1, 2014

An article titled “Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?”, published in the European Respiratory Review, the authors say that improved care in pulmonary arterial hypertension has led to increased longevity for patients, with a paralleled evolution in the nature of their needs. There is more focus on

“Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?”, European Respiratory Review, December 1, 2014 Read Post »

TRANSLATE »
Scroll to Top